← Leaderboards
Adam R Renslo
University Of California, San Diego
$18,732,835
Attributed
$26,152,019
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.8M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,152,019 · 12
By mechanism
R01$17,468,159 · 6
U19$6,211,475 · 1
R21$1,337,144 · 3
R41$1,135,241 · 2
Top collaborators
- Yu Chen7 shared
- Michelle Arkin5 shared
- Eric Collisson5 shared
- Michael John Evans4 shared
- Daniel L Minor3 shared
- Alan R. Saltiel3 shared
- Matthew S Bogyo2 shared
- Stacie Canan2 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Alan R. Saltiel$35,794,253
- Michelle Arkin$14,172,629
- Peng Zhao$3,119,420
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsCellsIn VivoDesignIn VitroSmall MoleculePropertyAnalogResistanceTissuesAnimal ModelPathway InteractionsLeadBaseMouse ModelIronDrug Delivery SystemsDrug DiscoveryStructureToxic EffectPharmacologyScaffoldInhibitor/AntagonistDose
Grant awards (42)
Evolution and inhibition of carbapenemase in beta-lactam resistance$779,337
R01 · FY2025 · AI
Understanding efficacy and FE(II)-Promoted Activation of 1,2,4-Trioxolanes in cancer$660,920
R01 · FY2025 · CA
Development of caspase-6 inhibitors for treatment of NASH$626,805
R01 · FY2025 · DK
Evolution and inhibition of carbapenemase in beta-lactam resistance$748,760
R01 · FY2024 · AI
Development of caspase-6 inhibitors for treatment of NASH$671,821
R01 · FY2024 · DK
Understanding efficacy and FE(II)-Promoted Activation of 1,2,4-Trioxolanes in cancer$655,693
R01 · FY2024 · CA
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications$598,029
R01 · FY2024 · EB
Optimizing brain penetrance of caspase-6 inhibitors to treat neurodegenerative diseases$107,166
R41 · FY2024 · AG
Evolution and inhibition of carbapenemase in beta-lactam resistance$730,394
R01 · FY2023 · AI
Development of caspase-6 inhibitors for treatment of NASH$717,397
R01 · FY2023 · DK
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications$642,126
R01 · FY2023 · EB
Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer$625,125
R01 · FY2023 · CA
Optimizing brain penetrance of caspase-6 inhibitors to treat neurodegenerative diseases$180,375
R41 · FY2023 · AG
Medicinal chemistry core$6,211,475
U19 · FY2022 · AI · contact PI
Evolution and inhibition of carbapenemase in beta-lactam resistance$738,466
R01 · FY2022 · AI
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications$643,387
R01 · FY2022 · EB
Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer$626,596
R01 · FY2022 · CA
Chemical Methods for Ferrous Iron Dependent Drug Delivery$536,653
R01 · FY2022 · AI · contact PI
Evolution and inhibition of carbapenemase in beta-lactam resistance$751,397
R01 · FY2021 · AI
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications$675,144
R01 · FY2021 · EB
Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer$577,035
R01 · FY2021 · CA
Chemical Methods for Ferrous Iron Dependent Drug Delivery$536,653
R01 · FY2021 · AI · contact PI
Chemical Methods for Ferrous Iron Dependent Drug Delivery$536,653
R01 · FY2020 · AI · contact PI
Expanding the Chemical Biology of K2P Channels with Selective Cellular and In vivo Probes$473,430
R01 · FY2020 · MH · contact PI
Discovery of Novel Antimalarial Leads Targeting Translational Repression in Plasmodium parasites$239,484
R21 · FY2020 · AI · contact PI
Chemical Methods for Ferrous Iron Dependent Drug Delivery$533,884
R01 · FY2019 · AI · contact PI
Expanding the Chemical Biology of K2P Channels with Selective Cellular and In vivo Probes$469,656
R01 · FY2019 · MH · contact PI
Discovery of Novel Antimalarial Leads Targeting Translational Repression in Plasmodium parasites$214,372
R21 · FY2019 · AI · contact PI
Biophysical Fragment Screening and Structure Determination for Class A, B, and D Carbapenemases$193,625
R21 · FY2019 · AI · contact PI
Chemical Methods for Ferrous Iron Dependent Drug Delivery$531,946
R01 · FY2018 · AI · contact PI
Expanding the Chemical Biology of K2P Channels with Selective Cellular and In vivo Probes$488,166
R01 · FY2018 · MH · contact PI
Biophysical Fragment Screening and Structure Determination for Class A, B, and D Carbapenemases$246,975
R21 · FY2018 · AI · contact PI
Chemical Methods for Ferrous Iron Dependent Drug Delivery$396,684
R01 · FY2017 · AI · contact PI
Chemical Methods for Ferrous Iron Dependent Drug Delivery$396,638
R01 · FY2016 · AI · contact PI
Chemical Methods for Ferrous Iron Dependent Drug Delivery$396,429
R01 · FY2015 · AI · contact PI
Chemical Methods for Ferrous Iron Dependent Drug Delivery$355,844
R01 · FY2014 · AI · contact PI
Chemical Methods for Ferrous Iron Dependent Drug Delivery$347,091
R01 · FY2013 · AI · contact PI
Chemical Methods for Ferrous Iron Targeted Drug Delivery$235,063
R21 · FY2012 · AI · contact PI
Chemical Methods for Ferrous Iron Targeted Drug Delivery$207,625
R21 · FY2011 · AI · contact PI
Identification of Anti-HIV Lead Compounds Targeting Rev$288,691
R41 · FY2010 · AI · contact PI
Identification of Anti-HIV Lead Compounds Targeting Rev$296,696
R41 · FY2009 · AI · contact PI
Identification of Anti-HIV Lead Compounds Targeting Rev$262,313
R41 · FY2009 · AI · contact PI